The favorable prognostic impact of tissue inhibitor of matrix metalloproteinases-1 protein overexpression in breast cancer cells

APMIS

Volumn 111, Issue 11, 2003, Pages 1027-1036

  Nakopoulou, L ^a   Giannopoulou, I ^a   Lazaris, A Ch ^a   Alexandrou, P ^a   Tsirmpa, I ^a   Markaki, S ^a   Panayotopoulou, E ^a   Keramopoulos, A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Breast cancer; Immunohistochemistry; Multivariate analysis; Prognosis; Tissue inhibitor of metalloproteinases 1

Indexed keywords

GELATINASE A; MATRIX METALLOPROTEINASE; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; BREAST CANCER; CANCER CELL; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 2; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; STROMAL CELLS; SURVIVAL RATE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL;

EID: 0346244037     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2003.apm1111105.x     Document Type: Article

References (33)

1. Happner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix metalloproteinase family members in breast cancer represents a tumour-induced host response. Am J Pathol 1996;149:273-82.
2. McCarthy K, Maguire T, McGreal G, McDermott E, O'Higgis N, Duffy MJ. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer 1999;84:44-8.
3. Henriet P, Blavier L, Declerck YA. Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation. APMIS 1999;107:111-9.
4. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997;74:111-22.
5. Nemeth JA, Rafe A, Steiner M, Goolsby CL. TIMP-2 growth-stimulatory activity: a concentration-and cell type-specific response in the presence of insulin. Exp Cell Res 1996;224:110-5.
6. Chesler L, Goide DW, Bersch N, Johnson MD. Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinase-1. Blood 1995;86: 4506-15.
7. Lindsay CK, Thorgeirsson UP, Tsuda H, Hirohashi S. Expression of tissue inhibitor of metalloproteinase-1 and type IV collagenase/gelatinase messenger RNAs in human breast cancer. Hum Pathol 1997;28:359-66.
8. Yoshiji H, Gomez DE, Thorgeirsson UP. Enhanced RNA expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in human breast cancer. Int J Cancer 1996;69:131-4.
9. World Health Organization Histological Typing of Breast Tumours. Geneva: WHO, 1968.
10. Robbins P, Pinder S, de Klerk N, Dawkins H, Harvey J, Sterrett G, et al. Histological grading of breast carcinomas: a study of interobserver agreeement. Hum Pathol 1995;28:873-9.
11. Association of Directors of Anatomic and Surgical Pathology. Recommendations for the reporting of breast carcinoma. Hum Pathol 1990; 27:200-24.
12. rd edn, Philadelphia, Lippincott, 1989.
13. Fukuda Y, Imoto N, Koyama Y, Miyazawa Y, Nakano I, Hattori MF, et al. Immunohistochemical study on tissue inhibitors of metalloproteinases in normal and pathological human livers. Gastroenterol Jpn 1991;26:37-41.
14. Nakopoulou L, Katsarou S, Giannopoulou I, Alexandrou P, Tsirmpa I, Panayotopoulou E, et al. Correlation of tissue inhibitor of metalloproteinase-2 with proliferative activity and patients' survival in breast cancer. Mod Pathol 2002;15: 26-34.
15. Nakopoulou L, Giannopoulou I, Stefanaki K, Panayotopoulou E, Tsirmpa I, Alexandrou P, et al. Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J Pathol 2002;197:307-13.
16. McClelland RA, Wilson D, Leake R, Finley P, Nicholson RI. A multicentre study into the reliability of steroid receptor immunocytochemical assay quantification. Eur J Cancer 1991;27:711-5.
17. Nakopoulou L, Lazaris ACh, Kavantzas N, Alexandrou P, Athanassiadou P, Keramopoulos A, et al. DNA topoisomerase II-alpha immunoreactivity as a marker of tumor biology in invasive breast cancer. Pathobiology 2000;68:137-43.
18. Nakopoulou L, Panayotopoulou EG, Giannopoulou I, Alexandrou P, Katsarou S, Athanassiadou P, Keramopoulos A. Stromelyin-3 protein expression in invasive breast cancer: relation to proliferation, cell survival and patient's outcome. Mod Pathol 2002;15:1154-61.
19. Iwata H, Kobayashi S, Iwase H, Masaoka A, Fujimoto N, Okada Y. Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas. Jpn J Cancer Res 1996;87:602-11.
20. Mimori K, Mori M, Shiraishi T, Fujie T, Baba K, Haraguchi M, et al. Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer 1997;76:531-6.
21. Mori M, Mimori K, Sadanaga N, Inoue H, Tanaka Y, Mafune K, et al. Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in esophageal carcinoma. Int J Cancer 2000;88:575-8.
22. Inoue H, Mimori K, Shiraishi T, Kataoka A, Sadanaga N, Ueo H, et al. Expression of tissue inhibitor of matrix metalloproteinase-1 in human breast carcinoma. Oncol Rep 2000;7:871-4.
23. Luparello C, Avanzato G, Carella C, Pucci-Minafra I. Tissue inhibitor of metalloproteinase (TIMP)-1 and proliferative behaviour of clonal breast cancer cells. Breast Cancer Res Treat 1999;54:235-44.
24. Garbett EA, Reed MW, Stephenson TJ, Brown NJ. Proteolysis in human breast cancer. Mol Pathol 2000;53:99-106.
25. Hayakawa T, Yamashita K, Ocuchi E, Shinagawa A. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Cell Sci 1994;107:2373-9.
26. Li G, Fridman R, Kim HR. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res 1999;59:6267-5.
27. Clavel C, Polette M, Doco M, Binninger I, Birembaut P. Immunolocalization of matrix metalloproteinases and their tissue inhibitor in human mammary pathology. Bull Cancer 1992; 79:261-70.
28. Corcoran ML, Hewitt RE, Kleiner DE Jr, Stetler-Stevenson WG. MMP-2: expression, activation and inhibition. Enzyme Protein 1996;49: 7-19.
29. Ritter LM, Garfield SH, Thorgeirsson UP. Tissue inhibitor of metalloproteinases-1 (TIMP-1) binds to the cell surface and translocates to the nucleus of human MCF-7 breast carcinoma cells. Biochem Biophys Res Comm 1999;257: 494-9.
30. Hansen Ree A, Florenes VA, Berg JP, Mælandsmo GM, Nsland JM, Fodstad Ø. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res 1997;3:1623-8.
31. Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 2001;7:3113-9.
32. Remacle A, McCarthy K, Noel A, Maguire T, McDermott E, O'Higgins N, et al. High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int J Cancer 2000;89:118-21.
33. Scott KA, Holdsworth H, Balkwill FR, Dias S. Exploiting changes in the tumour microenvironment with sequential cytokine and matrix metalloprotease inhibitor treatment in a murine breast cancer model. Br J Cancer 2000; 83:1538-43.